eticyclidine

{{Short description|Medication}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Watchedfields = changed

| verifiedrevid = 437182986

| IUPAC_name = N-Ethyl-1-phenylcyclohexylamine

| image = Eticyclidine Structural formula V1.svg

| width = 165px

| tradename =

| legal_AU = S9

| legal_BR = F2

| legal_BR_comment = {{Cite web | vauthors = Anvisa | title = RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial | date = 2023-07-24 | trans-title = Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control | url = https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 | url-status = live | archive-url = https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 | archive-date = 2023-08-27 | access-date = 2023-08-27 | publisher = Diário Oficial da União | language = pt-BR | publication-date = 2023-07-25 }}

| legal_CA = Schedule III

| legal_DE = Anlage I

| legal_US = Schedule I

| legal_UK = Class B

| legal_UN = P I

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 2201-15-2

| ATC_prefix = none

| PubChem = 16622

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 15759

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = O8I1LL6A89

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 279924

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = C22716

| C=14 | H=21 | N=1

| smiles = CCNC1(CCCCC1)C2=CC=CC=C2

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C14H21N/c1-2-15-14(11-7-4-8-12-14)13-9-5-3-6-10-13/h3,5-6,9-10,15H,2,4,7-8,11-12H2,1H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = IFYLVUHLOOCYBG-UHFFFAOYSA-N

}}

PCE (Eticyclidine, CI-400) is a dissociative anesthetic drug with hallucinogenic effects. It is similar in effects to phencyclidine but is slightly more potent. PCE was developed by Parke-Davis in the 1970s and evaluated for anesthetic potential under the code name CI-400,{{cite journal | vauthors = Levy L, Cameron DE, Aitken RC | title = Observation on two psychotomimetic drugs of piperidine derivation--CI 395 (sernyl) and CI 400 | journal = The American Journal of Psychiatry | volume = 116 | issue = 9 | pages = 843-844 | date = March 1960 | pmid = 14416411 | doi = 10.1176/ajp.116.9.843 }} but research into PCE was not continued after the development of ketamine, a similar drug with more favourable properties.{{cite journal | vauthors = Kalir A, Edery H, Pelah Z, Balderman D, Porath G | title = 1-Phenycycloalkylamine derivatives. II. Synthesis and pharmacological activity | journal = Journal of Medicinal Chemistry | volume = 12 | issue = 3 | pages = 473-477 | date = May 1969 | pmid = 4977945 | doi = 10.1021/jm00303a030 }} Due to its similarity in effects to PCP, PCE was placed into the Schedule 1 list of illegal drugs in the 1970s, although it was only briefly abused in the 1970s and 1980s and is now little known.{{cite journal | vauthors = Morris H, Wallach J | title = From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | journal = Drug Testing and Analysis | volume = 6 | issue = 7-8 | pages = 614-632 | date = July 2014 | pmid = 24678061 | doi = 10.1002/dta.1620 }}